XTX Topco Ltd bought a new position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 249,800 shares of the biopharmaceutical company's stock, valued at approximately $412,000. XTX Topco Ltd owned approximately 0.22% of Fate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently added to or reduced their stakes in the company. Intech Investment Management LLC increased its stake in shares of Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 8,497 shares in the last quarter. SG Americas Securities LLC increased its stake in Fate Therapeutics by 30.6% in the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 10,511 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Fate Therapeutics by 0.5% during the third quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company's stock valued at $7,905,000 after purchasing an additional 10,863 shares during the period. American Century Companies Inc. boosted its position in shares of Fate Therapeutics by 6.6% during the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock worth $326,000 after purchasing an additional 12,295 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Fate Therapeutics by 9.6% during the 4th quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 14,532 shares in the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Stifel Nicolaus lowered their target price on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Thursday, March 6th. StockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, March 11th. Wedbush restated a "neutral" rating and set a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $5.43.
Read Our Latest Report on FATE
Fate Therapeutics Price Performance
Shares of FATE stock traded down $0.07 on Friday, hitting $1.28. The stock had a trading volume of 1,237,584 shares, compared to its average volume of 2,313,835. Fate Therapeutics, Inc. has a 12-month low of $0.66 and a 12-month high of $5.92. The stock has a market cap of $146.69 million, a price-to-earnings ratio of -0.78 and a beta of 2.41. The business has a 50 day moving average of $1.03 and a 200 day moving average of $1.69.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.13. The firm had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.57 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. As a group, research analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.
Fate Therapeutics Profile
(
Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
